SC
NRIX icon

Stempoint Capital’s Nurix Therapeutics NRIX Stock Holding History

Stempoint Capital’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.89M Buy
+315,226
New +$5.23M 0.94% 35
2024
Q4 		– Sell
-203,015
Closed -$4.56M – 71
2024
Q3 		$4.56M Sell
203,015
-258
-0.1% -$5.84K 1.37% 23
2024
Q2 		$4.24M Buy
+203,273
New +$3.17M 1.25% 27

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Stempoint Capital's NRIX Position: Q1 2026 in Review

Stempoint Capital opened a new position in Nurix Therapeutics (NRIX) in Q1 2026: 315,226 shares worth $4.89M. The stake represents 0.94% of the portfolio and ranks #35 among its holdings. This is a return to the name: Stempoint Capital previously reported a position in NRIX as recently as Q3 2024.

Stempoint Capital first reported a position in NRIX in Q2 2024 and has held it in 3 quarters since. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Stempoint Capital held 315,226 shares of Nurix Therapeutics worth $4.89M as of Q1 2026.
  • Nurix Therapeutics was a new Stempoint Capital position in Q1 2026.
  • Nurix Therapeutics made up 0.94% of Stempoint Capital's portfolio in Q1 2026, its #35 holding.
  • Stempoint Capital first reported a position in Nurix Therapeutics in Q2 2024 and has held it in 3 quarters since.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Stempoint Capital's 13F filing for Q1 2026, filed 15 May 2026.